Biogen Idec, Inc. (BIIB) Tops Q4 EPS by 7c; Issues Weak FY14 Profit Outlook
Tweet Send to a Friend
Biogen Idec, Inc. (NASDAQ: BIIB) reported Q4 EPS of $2.34, $0.07 better than the analyst estimate of $2.27. Revenue for ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
